Metabolomics

Metabolomic Identification of a Novel Pathway of Blood Pressure Regulation Involving Hexadecanedioate


Abstract—High blood pressure is a major contributor to the global burden of disease and discovering novel causal pathways of blood pressure regulation has been challenging. We tested blood pressure associations with 280 fasting blood metabolites in 3980 TwinsUK females. Survival analysis for all-cause mortality was performed on significant independent metabolites ($P<8.9 \times 10^{-4}$). Replication was conducted in 2 independent cohorts KORA (n=1494) and Hertfordshire (n=1515). Three independent animal experiments were performed to establish causality: (1) blood pressure change after increasing circulating metabolite levels in Wistar-Kyoto rats; (2) circulating metabolite change after salt-induced blood pressure elevation in spontaneously hypertensive stroke-prone rats; and (3) mesenteric artery response to noradrenaline and carbachol in metabolite treated and control rats. Of the 15 metabolites that showed an independent significant association with blood pressure, only hexadecanedioate, a dicarboxylic acid, showed concordant association with blood pressure (systolic BP: $\beta$ [95% confidence interval], 1.31 [0.83–1.78], $P=6.81 \times 10^{-5}$; diastolic BP: 0.81 [0.5–1.11], $P=2.96 \times 10^{-7}$) and mortality (hazard ratio [95% confidence interval], 1.49 [1.08–2.05]; $P=0.02$) in TwinsUK. The blood pressure association was replicated in KORA and Hertfordshire. In the animal experiments, we showed that oral hexadecanedioate increased both circulating hexadecanedioate and blood pressure in Wistar-Kyoto rats, whereas blood pressure elevation with oral sodium chloride in hypertensive rats did not affect hexadecanedioate levels. Vascular reactivity to noradrenaline was significantly increased in mesenteric resistance arteries from hexadecanedioate-treated rats compared with controls, indicating the shift to the left of the concentration–response curve ($P=0.013$). Relaxation to carbachol did not show any difference. Our findings indicate that hexadecanedioate is causally associated with blood pressure regulation through a novel pathway that merits further investigation. (Hypertension. 2015;66:422-429. DOI: 10.1161/HYPERTENSIONAHA.115.05544) ● Online Data Supplement

Key Words: blood pressure ■ fatty acid synthases ■ hypertension ■ metabolomics ■ mortality

Hypertension is the most prevalent modifiable risk factor for cardiovascular morbidity and mortality, with the World Health Organization estimating that the current 1 billion people with high blood pressure (BP) worldwide will rise to 1.5 billion by 2020. More importantly, 54% of stroke and 47% of ischemic heart disease are directly attributable to hypertension, thus primarily

Received March 25, 2015; first decision April 8, 2015; revision accepted April 27, 2015.
From the Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom (C.M., M.M., M.P., T.D.S., A.M.V.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (D.G., N.H.J.A., S.M.A., M.M.B., A.F.D., S.P.); Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, Germany (G.K., K.S.); Faculty of Medicine, University of Southampton; Southampton, United Kingdom (P.T., M.H.E., C.C.); Wellcome Trust Sanger Institute Human Genetics, Hinxton, United Kingdom (S.-Y.S., N.S.); MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom (S.-Y.S.); Chemical Analytics, Seibersdorf Labor GmbH, Seibersdorf, Austria (T.G., A.H., C.R.); Institute of Epidemiology II, Helmholtz Zentrum München, Germany (A.P., C.G.); Research Unit Molecular Epidemiology, Helmholtz Zentrum München, Germany (A.P., R.W.-S., T.X.); Cardiovascular and Metabolic Diseases, Pfizer Worldwide Research and Development, Cambridge, MA (M.J.B.); Edison Pharmaceuticals, Mountain View, CA (J.T.); Metabolon, Inc, Durham, NC (R.P.M.); Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom (C.C.); Scottish Pulmonary Vascular Unit, Golden jubilee Hospital, Glasgow, United Kingdom (A.C.C.); Department of Physiology and Biophysics, Weill Cornell Medical College in Qatar, Education City, Qatar Foundation, Doha, Qatar (K.S.); and Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom (A.M.V.).

*These authors contributed equally to this work.

This paper was sent to L. Gabriel Navar, Consulting Editor, for review by expert referees, editorial decision, and final disposition.
The online-only Data Supplement is available with this article at http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.115.05544/-/DC1.

Correspondence to Sandosh Padmanabhan, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom. E-mail sandosh.padmanabhan@glasgow.ac.uk

© 2015 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Hypertension is available at http://hyper.ahajournals.org

DOI: 10.1161/HYPERTENSIONAHA.115.05544
responsible for one quarter of the 52.8 million deaths recorded globally in 2010. The causation of hypertension is multifactorial and is related to perturbations in the pathways that regulate BP through renal, renin–angiotensin–aldosterone and autonomic systems. Despite the availability of numerous drugs for the treatment of hypertension, only one third of treated patients achieve target and this can be partially explained by the complexity of BP regulatory mechanisms that are different in each individual. New drug development for hypertension has essentially stalled during the past 10 years and there is a need to discover novel biological pathways for hypertension that will help identify novel drug targets or enable effective targeting of therapy. The hypothesis generating approach using genome-wide association studies while successful at identifying common variants associated with blood pressure have resulted in few tractable loci and novel pathways. Recent advances in metabolomics enable the capture of a snap-shot of the metabolic profile of the individual, allowing for the potential identification of novel pathogenic pathways. In this study, we performed nontargeted metabolic screening to discover metabolites associated with BP integrating data from dietary intake and mortality outcomes in a large female twin cohort from the United Kingdom and replicated our findings in 2 independent populations from Germany and England. Finally, we use animal models to establish causality.

Methods

Discovery Population
Metabolomic data were analyzed for 3980 female participants from TwinsUK without renal impairment (estimated glomerular filtration rate >60 mL/min per 1.73 m²) and not on any BP-lowering medications. The study was approved by St. Thomas Hospital Research Ethics Committee. All participants provided informed written consent. Further details are available in the online-only Data Supplement. TwinsUK metabolomics, and phenotypic data are publicly available on request on the department website (http://www.twinsuk.ac.uk/data-access/accessmanagement/).

Metabolomic Profiling
Nontargeted detection and quantification of 280 structurally named biochemicals was conducted by Metabolon, Inc (Durham, NC) on 1052 serum and 5003 plasma fasting samples from TwinsUK participants as previously described.

Replication Cohorts for Hexadecanedioate

KORA
We included 1494 individuals comprising nearly equal numbers of males and females, with BP, metabolomics data and without renal impairment (estimated glomerular filtration rate >60 mL/min per 1.73 m²) from the population-based KORA S4 study (Cooperative Health Research in the Region of Augsburg).11

Hertfordshire Cohort
One thousand five hundred fifteen comprising nearly equal numbers of males and females from the Hertfordshire Cohort in whom BP and plasma hexadecanedioate levels had been measured were included in analyses. This is a unique population-based cohort of older individuals born in Hertfordshire in the 1930s and still living there now. Plasma hexadecanedioate levels were measured with mass spectrometer at the Seibersdorf Labor GmbH.

Thirty-five percent of both KORA and Hertfordshire individuals were on antihypertensive medication treatment. Therefore, 10/5 mm Hg was added to the on treatment BP in the analysis to adjust for treatment effect.

Animal Studies
All animal procedures performed were approved by the UK Home Office. Male spontaneously hypertensive stroke-prone (SHRSP) rats and Wistar–Kyoto (WKY) rats (Harlan, Wyton, United Kingdom) were used. Eleven-week-old male WKY rats were treated with hexadecanedioic acid (250 mg/kg per day; n=6) or vehicle control (n=6) for 4 weeks. Twelve-week-old male SHRSP rats received 1% NaCl in drinking water for 3 weeks (n=6). Systolic BP (SBP) was measured by tail plethysmography in conscious, restrained animals. BP recordings were carried out before salt challenge or hexadecanedioic acid treatment and during the final week of treatment. An average of 6 to 8 pressure readings were taken for each rat per sitting. Statistical comparisons were made using Student t test. In addition, telemetry probes (TA11PAC40, Data Sciences International) were implanted at 10 weeks of age with 1 week of recovery before administration of hexadecanedioic acid (250 mg/kg per day; n=5) or vehicle control (n=5) for 3 weeks in WKY rats. Statistical analysis of the radiotelemetry data was carried out using appropriate summary measures followed by Student t test.

Mesenteric resistance artery function was assessed by wire myography. Resistance arteries were dissected from connective tissue and segments (n=22 mm in length) were mounted as ring preparations on 2 stainless steel wires in a 4-channel small vessel myograph (Danish MyoTechnology, Aarhus, Denmark). One wire was attached to a force transducer and the other to a micrometer. After a 30-minute rest period, vessels were set to normalized internal diameter (L₀) to achieve optimal contraction. Internal diameter was calculated using the following equation: L₁=L₀+Pr (where L₀ is the internal radius). After further 60 minutes, contractile responses to 10 μmol/L KCl were examined, followed by washout. A cumulative concentration–response curve to noradrenaline, 10 nmol/L to 30 μmol/L was performed. In addition, vessels were preconstricted to the effective concentration (EC₅₀) of noradrenaline and a concentration–response curve for carbachol (10 nmol/L–10 μmol/L) was obtained. Area under the curve data were calculated from the mesenteric artery response curves (n=10 hexadecanedioate treated and n=9 control) and statistical comparisons were made using Student t test.

Plasma hexadecanedioate levels were measured with mass spectrometer at the Seibersdorf Labor GmbH.

Statistical Analysis
Statistical analysis was carried out using Stata version 11 and R. Quality control of metabolomics data was carried out as previously described. We inverse normalized the data as the metabolite concentrations were not normally distributed. To avoid spurious false-positive associations because of small sample size, we excluded metabolic traits with >20% missing values. We imputed the missing values using the minimum run day measures.

Metabolites Associated With SBP and Diastolic BP
Metabolites associated with SBP and diastolic BP (DBP) were identified by linear regression adjusting for age, body mass index, metabolite batch, and family relatedness. Individual metabolites significantly associated with SBP and DBP (Bonferroni P<8.9x10⁻⁹ for 280 metabolites×2 traits) were included in a backward regression model reducing the number of predictors for SBP and DBP.

As dietary factors (fruit and vegetable intake and alcohol intake) and genotype risk scores are known to affect BP to varying levels, we tested their effect on the association between the metabolites represented independent variables using random intercept linear regressions.

In KORA and Hertfordshire, the covariates in the regression model included age, sex, and body mass index.

Association With Mortality
Kaplan–Meier survival analysis (univariate) and Cox proportional hazards modeling (adjusted for age, body mass index, and stratified
Direction of effect for both BP and mortality, while in contrast, the direct association between dihomo-linoleate (20:2n6) or caffeine and blood pressure did not translate into increased mortality risk.

Replication Analysis of top two metabolites Hexadecanedioate BP Association in KORA and Hertfordshire

The replication KORA S4 cohort included 1494 individuals (males=776 and females=718), whereas the Hertfordshire cohort included 1515 individuals (males=765 and females=750). Hexadecanedioate (SBP: $β$ [95% confidence interval], 1.42 [0.37–2.47], $P=0.01$; DBP: 0.64 [0.09–1.19], $P=0.02$) was significantly associated with both SBP and DBP in the KORA S4 population after adjusting for covariates. Hexadecanedioate was also significantly associated with both SBP and DBP in the Hertfordshire cohort (SBP: 1.58 [0.56–2.60], $P=0.002$; DBP: 0.56 [0.02–1.1], $P=0.04$; Table S4 in the online-only Data Supplement).

Causal Role for Hexadecanedioate in Increasing BP

Circulating levels of hexadecanedioate were significantly increased in WKY rats after treatment with oral hexadecanedioic acid for 4 weeks compared with untreated controls ($P=0.014$; Figure 1A). Hexadecanedioate-treated WKY rats also demonstrated a small but significant increase in SBP ($Δ$SBP, 8.38±2.75 mm Hg; $P=0.019$) compared with untreated controls when measured by tail-cuff plethysmography (Figure 1B). The hexadecanedioic acid induced increase in BP in WKY rats was further confirmed by radiotelemetry, which demonstrated a delayed separation of SBP and mean arterial pressure between control and hexadecanedioate-treated animals occurring after day 15 of treatment, which did not attain statistical significance ($P=0.084$, SBP hexadecanedioate versus control; $P=0.057$, mean arterial pressure hexadecanedioate versus control), but did not show any separation with DBP or heart rate (Figure 1F and 1H). Three weeks of 1% NaCl administration in drinking water significantly elevated SBP in SHRSP rats ($Δ$SBP, 21.33±5·92 mm Hg; $P=0.014$; Figure 1D), however, plasma hexadecanedioate levels were not modified by salt challenge (Figure 1C). Baseline circulating hexadecanedioate levels were significantly higher in SHRSP rats compared with untreated age-matched WKY rats ($P=0.0001$). Vascular reactivity to noradrenaline was significantly increased in mesenteric resistance arteries from hexadecanedioate-treated rats compared with controls, indicated by the shift to the left of the concentration response curve (hexadecanedioate area under the curve 100.8±9.3 versus control area under the curve 81.7±8.8; $P=0.013$; Figure 2A). Relaxation to carbachol was not different in mesenteric resistance arteries from control and hexadecanedioate-treated WKY rats (Figure 2B).

Discussion

In the largest investigation to date on metabolomic profiling for BP, we have identified a putative novel pathway for BP regulation involving a dicarboxylic acid (hexadecanedioate) with a causal role supported by in vivo studies in rats. After screening 280 metabolites in the discovery TwinsUK cohort, we identified 77 metabolites significantly associated with SBP...
or DBP. To limit the number of metabolites to take forward for replication, we narrowed the list down to 15 independent metabolites through a series of sequential analytic steps to address the observed correlations between metabolite levels. These 15 metabolite signals were also independent of fruit/vegetable or alcohol intake and BP genome-wide association study risk score all of which affect BP to varying levels. To minimize the risk of reverse causation as an explanation for our findings, we tested the association between these metabolites with all-cause mortality in the discovery cohort. Although incident hypertension or cardiovascular mortality would have been ideal longitudinal phenotypes to analyze, these were unavailable in the discovery cohort. As high BP does increase the risk of both all-cause and cardiovascular mortality, we used all-cause mortality to filter metabolites for replication.

Only 3 metabolites (dihomo-linoleate (20:2n6), hexadecanedioate, and caffeine) showed significant associations with mortality in TwinsUK. More importantly, only 1 metabolite (hexadecanedioate) of the 3 showed directionally consistent and significant associations with both BP and mortality suggesting a possible sustained detrimental effect of higher levels of the metabolite through increased BP. This is in contrast to the other 2 metabolites, dihomo-linoleate (20:2n6) and caffeine, which did not increase mortality, despite showing positive associations with BP. In addition, we performed survival analysis on other dicarboxylic acids (tetradecanedioate, octadecanedioate, and dodecanedioate) and none of them showed significant concordant association with mortality. Although our discovery analysis included only women who were not on any BP-lowering medications, we are able to demonstrate generalizability of our results for hexadecanedioate through replication in the KORA and Hertfordshire study, both of which included male and female subjects and hypertensive subjects on treatment. Our discovery results are maintained

### Table 2. Results From Single Metabolite Analysis of the Metabolites Significant in Backward Regression and Metabolite Levels and Risk of All-Cause Mortality in TwinsUK

<table>
<thead>
<tr>
<th>Metabolite Super-p Sub-p</th>
<th>SBP</th>
<th>DBP</th>
<th>Cox-Model All-Cause Deaths=184</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sub-p Metabolite</td>
<td>β</td>
<td>95% CI</td>
<td>P Value</td>
</tr>
<tr>
<td>Phenylacetylglutamine a-a Phenylalanine and tyrosine metabolism</td>
<td>-1.04 (−1.53 to -0.55)</td>
<td>3.64×10⁻⁵</td>
<td>0.06 (−0.97 to -0.34)</td>
</tr>
<tr>
<td>Lactate ch Glycolysis, gluconeogenesis, pyruvate metabolism</td>
<td>1.51 (0.99–2.02)</td>
<td>1.24×10⁻⁸</td>
<td>0.94 (0.61–1.27)</td>
</tr>
<tr>
<td>Octanoylcarnitine l Carnitine metabolism</td>
<td>1.37 (0.91–1.83)</td>
<td>4.98×10⁻⁹</td>
<td>0.78 (0.48–1.08)</td>
</tr>
<tr>
<td>Stearoylcarnitine l Carnitine metabolism</td>
<td>0.98 (0.52–1.44)</td>
<td>3.29×10⁻⁵</td>
<td>0.67 (0.36–0.97)</td>
</tr>
<tr>
<td>Hexadecanedioate l Fatty acid, dicarboxylate</td>
<td>1.31 (0.83–1.78)</td>
<td>6.81×10⁻⁸</td>
<td>0.81 (0.5–1.11)</td>
</tr>
<tr>
<td>Tetradecanedioate l Fatty acid, dicarboxylate</td>
<td>1.57 (1.07–2.07)</td>
<td>8.45×10⁻¹⁰</td>
<td>0.88 (0.56–1.21)</td>
</tr>
<tr>
<td>10-Heptadecenoate (17:1n7) l Long chain fatty acid</td>
<td>1.3 (0.83–1.77)</td>
<td>6.45×10⁻⁸</td>
<td>0.9 (0.59–1.22)</td>
</tr>
<tr>
<td>Dihomo-linoleate (20:2n6) l Long chain fatty acid</td>
<td>1.94 (1.5–2.38)</td>
<td>1.40×10⁻¹⁷</td>
<td>1.13 (0.82–1.44)</td>
</tr>
<tr>
<td>Nonadecanoate (19:0) l Long chain fatty acid</td>
<td>0.91 (0.47–1.36)</td>
<td>6.86×10⁻⁵</td>
<td>0.61 (0.31–0.92)</td>
</tr>
<tr>
<td>Palmitate (16:0) l Long chain fatty acid</td>
<td>1.85 (1.4–2.3)</td>
<td>7.76×10⁻¹⁸</td>
<td>1.09 (0.78–1.4)</td>
</tr>
<tr>
<td>5-Dodecenoate (12:1n7) l Medium chain fatty acid</td>
<td>1.76 (1.3–2.23)</td>
<td>1.97×10⁻¹³</td>
<td>0.94 (0.63–1.25)</td>
</tr>
<tr>
<td>4-Androsten-3β,17β-diol disulfate 1* l Sterol/Steroid</td>
<td>1.82 (1.25–2.38)</td>
<td>3.95×10⁻¹⁰</td>
<td>1.25 (0.87–1.63)</td>
</tr>
<tr>
<td>Cortisol l Sterol/Steroid</td>
<td>1.66 (1.21–2.11)</td>
<td>6.68×10⁻¹³</td>
<td>0.89 (0.58–1.2)</td>
</tr>
<tr>
<td>HWESASXX* p Polypeptide</td>
<td>0.94 (0.48–1.4)</td>
<td>5.87×10⁻⁵</td>
<td>0.72 (0.42–1.03)</td>
</tr>
<tr>
<td>Caffeine x Xanthine metabolism</td>
<td>1.46 (1.1–1.92)</td>
<td>6.88×10⁻¹⁰</td>
<td>0.96 (0.65–1.27)</td>
</tr>
</tbody>
</table>

Analyses adjusted for age, body mass index, metabolite batch, and family relatedness. Metabolites are inversed normalize to have mean=0 and SD=1. Blood pressure association analyses performed in 3980 female subjects with both BP and metabolomic data available; survival analysis performed on 4894 individuals with metabolomic data available. a-a indicates amino-acid; ch, carbohydrate; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; l, lipid; p, peptide; SBP, systolic blood pressure; and x, xenobiotic. The biochemical identities of the metabolites in the Metabolon panel are determined using pure substances. * indicates cases where metabolite identities were inferred based on their fragmentation spectrum and other biochemical evidence.
even after inclusion of individuals from the TwinsUK cohort who were on BP-lowering medications (Table S5 in the online-only Data Supplement). We recognize that the lack of concordant mortality effect with BP association for dihomo-linoleate (20:2n6) and caffeine does not conclusively exclude a pathological effect, but we think further analyses of

Figure 1. A, Plasma hexadecanedioate levels (ng/mL) and (B) systolic blood pressure (SBP; mm Hg) in Wistar–Kyoto (WKY) rats treated with 250 mg/kg per day hexadecanedioate or vehicle for 4 weeks (n=6). C, Plasma hexadecanedioate levels (ng/mL) and (D) SBP (mm Hg) in spontaneously hypertensive stroke prone (SHRSP) rats (n=6) pre- and postadministration of 1% NaCl in drinking water for 3 weeks. "P<0.05 vs respective untreated group. Radiotomeasurement (24-h averages) of (E) systolic blood pressure, (F) mean arterial pressure, (G) diastolic pressure, and (H) heart rate in WKY rats treated with hexadecanedioic acid (250 mg/kg per day, n=5) or vehicle (n=5) for 3 weeks.
which resulted in a further increase in BP but no change in circ-
elars in the SHRSP rat before and after administration of salt.

In the second experiment, we measured hexadecanedioate lev-
an increase in BP, both of which were statistically significant.
an increase in circulating hexadecanedioate levels along with
intake of hexadecanedioate, normotensive WKY rats showed
of hexadecanedioate on BP regulation. In the first, after oral
ration of SBP and mean arterial pressure between control and

data, the increase in SBP and mean arterial pressure is not
induced rise in blood pressure. From the radio-telemetry
and to determine the time course of the hexadecanedioate-
provide confirmation of our tail-cuff plethysmography data
posthexadecanedioate WKY rats. We used radio-telemetry to
rats at baseline, and levels were similar between SHRSP and
dioate levels in the SHRSP rats were higher than that of WKY

The lack of a detrimental effect on survival for caffeine levels
is warranted before further functional studies are conducted.

Multiple strands of evidence from related pathways point
to potential mechanisms that can inform future studies to dis-
sect the hexadecanedioate BP association. Nonesterified fatty
acids reduce Na⁺K⁺-ATPase activity in vascular smooth mus-
cle cells through increase in intracellular Na⁺ and decrease of
ative fatty acid (obesity, starvation, diabetes mellitus, and chronic alcohol consumption), as well as disturbances in
β-oxidation.22,23 A lack of carnitine can lead to increased
β-oxidation.24 In our data, we find that levels of hexadec-
anedioate are indeed negatively correlated with carnitine
(β=−0.05; 95% confidence interval, [−0.08 to −0.01]; P=0.01).

Interestingly, a recent report showed multiple dicarboxylic
acids, including hexadecanedioate, to be significantly accumu-
lated in pulmonary arterial hypertension tissues indicating a
disruption of β-oxidation and an increase of ω-oxidation in this
condition and pointing to a putative role in elevating pressure
in both the systemic and the pulmonary circulations.27 Indeed
metabolic dysfunction and acquired mitochondrial abnormali-
ties leading to abnormal glycolytic and fatty acid metabolism
are now recognized as a potential biological mechanism lead-
ing to both pulmonary vascular remodeling with aberrant cel-
ular proliferation and apoptosis, and in the development of
right ventricular failure.28,29 Fatty acid metabolism could offer a
ovel therapeutic pathway, which would potentially target both
pulmonary vasculature and the right ventricle.

Some of the specific functional effects of hexadecanedio-
ate have been studied using β,β'-tetramethylhexadecanedioic
acid (MEDICA 16), which is not metabolized and hence the
effects of downstream metabolic products that may mask the
effects of hexadecanedioate are minimized. MEDICA 16 has
been shown to be effective as a hypolipidemic and antiobe-
osity/anti-insulin resistance agent in experimental models,30,31
and has a liver-specific calorogenic-thyromimetic action char-
acterized by a decrease in liver phosphate potential and liver
redox potential with an increase in oxygen consumption, but
dihomo-linoleate (20:2n6) in larger cohorts with more events
is warranted before further functional studies are conducted.
The lack of a detrimental effect on survival for caffeine levels
reflects the acute effect of caffeine on blood pressure, which
varies with intake. We had a priori excluded individuals with
renal impairment in our analysis and adjusting for estimated
glomerular filtration rate did not alter the BP hexadecanedioate
association. There is evidence that long-chain fatty acids, such
as docosahexaenoic acid influence BP potentially through an
effect on large-conductance Ca(2+)- and voltage-activated K+
(BK) channels,21 but this was not evident in our study.

We performed 3 in vivo experiments to establish causality
of hexadecanedioate on BP regulation. In the first, after oral
intake of hexadecanedioate, normotensive WKY rats showed
an increase in circulating hexadecanedioate levels along with
an increase in BP, both of which were statistically significant.
In the second experiment, we measured hexadecanedioate lev-

eels in the SHRSP rat before and after administration of salt,
which resulted in a further increase in BP but no change in cir-
culating hexadecanedioate levels. Interestingly hexadecane-
dioate levels in the SHRSP rats were higher than that of WKY
rats at baseline, and levels were similar between SHRSP and
posthexadecanedioate WKY rats. We used radio-telemetry to
provide confirmation of our tail-cuff plethysmography data
and to determine the time course of the hexadecanedioate-
induced rise in blood pressure. From the radio-telemetry
data, the increase in SBP and mean arterial pressure is not
immediate after hexadecanedioate administration, with separa-
tion of SBP and mean arterial pressure between control and
hexadecanedioate-treated animals occurring after day 15 of
treatment. This suggests that the mechanism by which hexa-
decanedioate affects BP is probably through secondary down-
stream pathways activated by higher hexadecanedioate levels.
The increased vascular reactivity to noradrenaline shown by
mesenteric arteries of hexadecanedioate-treated rats point to
a vascular mechanism underlying the association of hexadec-
anedioate and blood pressure. Although these are preliminary
data, overall they provide strong corroborative evidence of a
causal role for hexadecanedioate in modulating blood pres-
sure and support further research in validating and elucidating
the mechanisms.

Hexadecanedioic acid is a long-chain dicarboxylic acid,
which is generated during fatty acid ω-oxidation and thence
metabolized by β-oxidation in peroxisomes. ω-oxidation is
a minor metabolic pathway that occurs in the endoplasmic
reticulum and also contributes to 5% to 10% of total fatty acid
metabolism in the liver. ω-Oxidation is increased in condi-
tions that are characterized by increased levels of mono-car-
boxylic free fatty acid (obesity, starvation, diabetes mellitus,
and chronic alcohol consumption), as well as disturbances in
β-oxidation.22,23 A lack of carnitine can lead to increased
ω-oxidation.24 In our data, we find that levels of hexadec-
anedioate are indeed negatively correlated with carnitine
(β=−0.05; 95% confidence interval, [−0.08 to −0.01]; P=0.01).

Figure 2. Mesenteric resistance artery contractile response to
noradrenaline (A) and relaxation to carbachol (B) in control (n=9)
and hexadecanedioate treated (n=10) WKY rats. AUC indicates
area under the curve.

Interestingly, a recent report showed multiple dicarboxylic
acids, including hexadecanedioate, to be significantly accumu-
lated in pulmonary arterial hypertension tissues indicating a
disruption of β-oxidation and an increase of ω-oxidation in this
condition and pointing to a putative role in elevating pressure
in both the systemic and the pulmonary circulations.27 Indeed
metabolic dysfunction and acquired mitochondrial abnormali-
ties leading to abnormal glycolytic and fatty acid metabolism
are now recognized as a potential biological mechanism lead-
ing to both pulmonary vascular remodeling with aberrant cel-
ular proliferation and apoptosis, and in the development of
right ventricular failure.28,29 Fatty acid metabolism could offer a
novel therapeutic pathway, which would potentially target both
pulmonary vasculature and the right ventricle.

Some of the specific functional effects of hexadecanedio-
ate have been studied using β,β'-tetramethylhexadecanedioic
acid (MEDICA 16), which is not metabolized and hence the
effects of downstream metabolic products that may mask the
effects of hexadecanedioate are minimized. MEDICA 16 has
been shown to be effective as a hypolipidemic and antiobe-
osity/anti-insulin resistance agent in experimental models,30,31
and has a liver-specific calorogenic-thyromimetic action char-
acterized by a decrease in liver phosphate potential and liver
redox potential with an increase in oxygen consumption, but
its effect on BP has not been studied thus far. Endogenous hexadecanedioate may be a putative marker either for the perturbations in immunologic processes or lipid β-oxidation that lead to high blood pressure, and further studies are needed to clarify the mechanism. Human metabolomic studies are potentially confounded by diet or drug effects, as well as other comorbidities. In our discovery study, we tested for the effect of diet and alcohol intake, excluded individuals who were on antihypertensive therapy and looked for corroborative evidence of increased mortality.

We note some limitations to our study. All the human metabolomic analysis is cross-sectional so we cannot dissect causality from it alone. We used all-cause mortality rather than incident hypertension or cardiovascular mortality because of lack of data. Our 2-stage approach was designed to take forward a limited number of metabolites for replication to attenuate the multiple testing burden and the high false-positive rates seen in high-throughput discovery studies. We recognize that hexadecanedioate may be a low-hanging fruit and that there will exist other valid metabolites that are associated with BP. Although our in vivo studies support a role for hexadecanedioate in BP regulation, the exact causal pathway is not established. The increased vascular reactivity to noradrenaline in hexadecanedioate-treated rats may be either a consequence of hypertension or a cause, and this needs to be elucidated in future experiments.

Perspectives

Using a multilayered approach comprising metabolomic profiling in twins followed by replication studies and in vivo experiments, we have uncovered a putative novel pathway of BP regulation involving a dicarboxylic acid, hexadecanedioate. Preliminary studies from pulmonary hypertension suggesting an accumulation of dicarboxylic acids in this condition supports a possible vascular role for dicarboxylic acids in increasing pressure in both the systemic and pulmonary circulation. Studies on fatty acid metabolism could offer a novel therapeutic pathway, which would potentially target both pulmonary and systemic hypertension. Our finding may indeed be a low-hanging fruit but as it points to a previously unknown pathway for blood pressure regulation these results should stimulate further studies specifically along 2 strands—(1) confirm and elucidate the mechanistic underpinnings of the role of fatty acid β-oxidation in blood pressure regulation and (2) identify other true causal metabolite associations.

Acknowledgments

We wish to express our appreciation to all study participants of the TwinsUK, KORA, and Hertfordshire studies.

Sources of Funding

This work was supported by: the EU Framework Programme 7 small-scale focused research collaborative project EurHEALTHAging 277849; Metabolomic analysis was funded by Pfizer; TwinsUK was funded by the Wellcome Trust (Ref: 081878/Z/06/Z); European Community’s Seventh Framework Programme (FP7-2007–2013). The study also receives support from the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s and St. Thomas’ National Health Service (NHS) Foundation Trust and NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. T. Spector is an NIHR senior investigator and is holder of an ERC Advanced Principal Investigator award. S.-Y. Shin is supported by a Post-Doctoral Research Fellowship from the Oak Foundation. N. Soranzo team is supported by the Wellcome Trust (Grant Codes WT098051 and WT091310), the EUF7P (EPIGENESYS Grant Code 257082 and BLUEPRINT Grant Code HEALTH-F5-2011–282510). The KORA research platform (KORA, Cooperative Research in the Region of Ausburg) was initiated and financed by the Helmholtz Zentrum München—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. The Hertfordshire Cohort Study was supported by the Medical Research Council (MRC) of Great Britain; Arthritis Research UK; and the International Osteoporosis Foundation. The work herein was also supported by the NIHR Nutrition Biomedical Research Centre, University of Southampton, and the NIHR Musculoskeletal Biomedical Research Unit, University of Oxford.

Disclosures

R.P. Mohney is an employee of Metabolon, Inc. M.J. Brosnan is full time employee and share holder of Pfizer. J. Trimner is a share holder of Pfizer. The other authors report no conflicts.

References

What Is New?

- From a pool of 77 metabolites, which showed significant associations with systolic blood pressure (BP) or diastolic BP, we narrowed the list down to three metabolites (dihomo-linoleate (20:2n6), hexadecanedioate, and caffeine) that were also significantly associated with mortality in the same cohort and replicated in the KORA and Hertfordshire populations.
- Only hexadecanedioate showed concordant directionality of effect for both BP and mortality.
- We showed that hexadecanedioate is causally related to BP change using an animal model.

What Is Relevant?

- The results presented contribute to advance our understanding of the causation of hypertension by finding a new potential pathway of BP regulation.

Summary

Circulating levels of the dicarboxylic acid hexadecanedioate points to a novel pathway for BP regulation that merits further study.